Best MicroCap, Small Cap and Emerging Stocks to Buy - J Charles Assets
We search for the smart new growing companies to invest in with stock deals to watch in pharmacuetical and digital verticals.
Earnings easily topped expectations.
Any guesses of where it'll move from here?
AAPL and ILMN, romantic ideal couple.
Nice move up. OT Must see AVEO...close to moving up higher...come to the Yahoo message board. Rx for Renal cancer-Tivozanib- Recommended for Approval. Date for Approval end Aug...SOON.
down after hours?
Test kit is huge deal should bring significant move.
(AXSM) Market Cap $90 M/Cash $55 M / 5x BIG Phase 3 programs in various indications targeting large Markets with first results in Q3 2017 =20 BAGGER ..FANTASTIC OPPORTUNITY !
Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $90 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .
This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL
Market-Cap: $90 Million Cash: $55 Million(cash runway into the first quarter of 2019.) Price:$3.90
Shares Out: 23.5 Million
Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.
Yahoo Finance Insights
ILMN is down -4.92% to 168.94
Wait, didn't this scam missed earnings and downwardly revised the guidance big time. Oh I forgot we are in the bubble so all that doesn't matter. But wait what will happen to #$%$ stocks like these when bubble finally goes bonker? It may happen starting Monday. Nasdaq wouldn't stop until it has falled 20-30% or more. Some are saying 80% drop, worst ever after 1929 and 2000.
With a positive 700 million in equity after taking cash minus debt into account, and over 25 BILLION in stock value, this company could easily take out EXAS which poses an existential threat to the GRAIL initiative. The time to act is now however, soon their 3 Billion market cap will look like peanuts (See news re: UNH endorsement of the Cologuard Test and the non invasive test they've got on the front burner set to replace Lung Biopsy as a diagnostic tool. This could be highly accretive for ILMN and furthermore, I would HATE to see AMGN beat them to the punch and score here.
Bought $181, not long ago; today added $176
does Illumina buy Exact Science's (exas) or does Thermo Fisher (tmo) buy Exas first?
Earnings always scary with this company , feeling better.
Hey shorts - you were too clever by half in trying to peddle your fake news contamination story in front of earnings. How ya doing?